智通财经APP讯，康哲药业(00867)发布公告，集团附属公司RxilientMedical于2026年11月3日获得新加坡卫生科学局(HSA)批准磷酸芦可替尼乳膏(“产品”或“Lumirix®”)(白癜风适应症)新药上市许可申请(NDA)。产品用于治疗12岁及以上青少年和成人患者伴面部受累的非节段型白癜风，是新加坡首款且唯一直接针对白癜风病理生理机制的外用处方药，满足长期未被满足的临床需求。
本次获批，填补了新加坡白癜风治疗领域存在的空白。除新加坡外，截至目前Rxilient Medical已推动Lumirix®(白癜风适应症)于香港特别行政区、澳门特别行政区及台湾地区正式启动销售。
康哲药业自2022年起启动“产业国际化”战略，以新加坡为新兴市场业务枢纽，构筑“研、产、销”全产业链高效协同的价值闭环。RxilientMedical是集团进军新兴市场的商业化子公司，其以“全球本土化”为核心策略，通过覆盖药品引进、开发注册、营销推广的全链条商业化能力，致力于将全球创新疗法带入新兴市场，造福当地患者。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.